Both natural and therapy-driven tumor-targeting immune responses generally involve the recognition of malignant cells by CD8+ cytotoxic T lymphocytes (CTLs) or natural killer (NK) cells, culminating with the release of effector molecules such as granzyme B (GZMB) and interferon gamma (IFNG, best known as IFNγ) [1]. This evidence concerns the gene IFNG and neoplasm.